Correspondence  by unknown
ischemic adaptation in group C versus group N. Unfortunately, the
authors have not taken into account that the ECG measures the sum
of CR and IP and not IP, as they indicated for the group N (see above).
As long as one cannot be certain that the instrument for the measure-
ment of collateral flow is very sensitive, it is conceptually wrong to
disregard a contribution of CR to IT in patients with (possibly) poor
collateral channels. Considering the quality of their Figure 1, it is
questionable whether the accuracy and precision of MCE are sufficient
to discern subtle changes in collateral perfusion during subsequent
occlusions, a prerequisite to answer the question of this study. Using
the alternative conclusion, the interpretation of the data of the study is
straightforward:
1. MCE was sharp enough to detect collateral perfusion during the
first occlusion in group C.
2. The group with well developed collateral channels did not reveal
marked ST segment changes during the first occlusion because the
collateral channels were sufficient to (almost) prevent myocardial
ischemia. “Sufficient” collateral channels providing a flow $30%
compared with the antegrade flow through the patent vessel prevent
intracoronary ECG signs of ischemia (2,3).
3. Absent ECG signs to start with in group C could not diminish
further during subsequent occlusions, even in the presence of IP or
prominent CR, or both (i.e., in this situation, the ECG was too blunt
to detect IT due to CR or IP). However, it did not detect no IP.
4. Conversely, MCE was too blunt to detect collateral perfusion
during the first occlusion in group N.
5. The collateral perfusion present but undetected in group N was
insufficient to prevent ECG signs of myocardial ischemia. It cannot be
determined whether the reduction of ST segment elevation during
subsequent occlusions was caused by CR or IP. Data from our
laboratory using intracoronary measurements of collateral flow indi-
cate that CR contributes to diminished ECG signs of ischemia during
repeated occlusions also in patients with few collateral channels.
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Reply
In animal experiments, it has been shown (1–3) that ischemic precon-
ditioning (IP) occurs in the absence of collateral recruitment (CR). In
a recent issue of the Journal (4), we studied whether IP also occurs in
humans. Myocardial contrast echocardiography (MCE) was used to
demonstrate that ischemic tolerance is acquired independently of CR
in patients during repeated coronary occlusion and hence to conclude
that IP and CR may play independent roles in ischemic adaptation in
humans as well as in animals.
Seiler assumed the presence of significant collateral circulation,
which was too poor to be detectable with MCE, and claimed that
collateral flow contributes to IP. His consideration is based on his own
data that intracoronary measurements of collateral flow increased
during repeated coronary occlusion in patients with few collateral
channels (5,6). Although the question he raised is quite interesting and
important, it is difficult to admit all of his claims. Epicardial collateral
flow may well be different from myocardial perfusion through collat-
eral channels. This difference has been clearly shown even in humans
by several groups. In addition, MCE is usually more sensitive than
other conventional techniques in detecting myocardial perfusion in
humans. Most important, the presence of epicardial collateral flow,
which is commonly assessed with coronary angiography and measure-
ments of coronary flow velocity patterns, is not necessarily evidence of
myocardial perfusion through collateral channels (7,8). Epicardial
collateral steal and changes in the hemodynamic state are included in
such features. Of course, there may well be some collateral perfusion
even in patients without MCE-determined collateral flow. However,
we may state that 1) MCE is the only currently available method for
assessing myocardial perfusion through the collateral circulation in the
clinical setting; 2) it is remarkable how the two groups of patients can
be differentiated with the data of MCE-determined collateral flow; and
3) many experimental investigations have shown evidence of IP
independently of CR. Accordingly, we may conclude that IP occurs
independently of CR during repeated coronary occlusions in humans,
at least in terms of MCE-determined CR.
YASUHIKO SAKATA, MD
TOHRU MASUYAMA, MD, FACC
The First Department of Medicine
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Angiographic Findings and Outcome in
Diabetic Patients With Myocardial
Infarction—the GUSTO-I Experience
In their article on the results of thrombolytic therapy in diabetic
patients, Woodfield et al. (1) found a higher mortality rate among
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patients with than among those without diabetes. This finding could
not be explained by the presence of heart disease itself, even after
clinical and angiographic variables were adjusted. Diabetes was thus
concluded to be an independent determinant of mortality at 30 days
after myocardial infarction. In a previous report (2), the same authors
observed that 24% of patients died of strokes, without noting the
variable of diabetes. Hemorrhagic strokes are known to be more
common in diabetic patients (3), and if we also consider that there
were more patients with hypertension in the diabetic group (53 vs. 34,
p , 0.001), this would explain the higher death rate in that group (4).
However, in their latter report, we do not know how many patients
died of strokes.
The authors did not find any difference in left ventricular function
after myocardial infarction, despite clinical variables that showed a
higher rate of heart failure among diabetic than nondiabetic patients.
The lack of association seems to be an issue of overmatching (5) rather
than of diabetic myocardiopathy, as the authors suggest. Patients with
reocclusion treated with either scheduled or emergency angioplasty
were not included in the analysis of ventricular function; it seems that
only a small number of patients with a patent infarct-related artery
(,20% of the whole group) were chosen. In other words, patients
selected had undergone successful thrombolysis with normal flow and
had no recurrent ischemia or angina pectoris. That said, we would like
to know how many of the 455 patients experienced heart failure so to
establish whether a difference in left ventricular function truly exists in
the diabetic group.
Finally, we would like to point out the possibility of a selection bias
in this study. The GUSTO-1 group included only patients who had
experienced ,6 h of pain, thus making the results valid only for those
diabetic patients admitted to coronary care units and not for the
greater number of patients first admitted into other hospital wards or
who simply remain at home during a silent heart attack. The mortality
rate for diabetic patients with an asymptomatic heart attack is consid-
ered to be 50%. This rate suggests that patients with a silent heart
attack could have a more serious coronary illness or that they may have
lacked access to timely care such as that proposed by the GUSTO-1
group (6).
JOSE´ M. IRIS, MD
MIGUEL A. VILLASIS-KEEVER, MD
Hospital General de Zona No. 8, IMSS
Hospital de Pediatrı´a, Centro Me´dico Nacional, Siglo XXI, IMSS
Playa Guitarro´n 420, Col. Militar Marte, CP 08830. Me´xico D.F., cp 08830
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Reply
Iris and Villasis have suggested that the mortality difference we noted
between patients with and without diabetes in the GUSTO-1 angio-
graphic study (1) may be at least in part due to differences in the
incidence of stroke between these groups. The stroke rates in patients
with and without diabetes were not significantly different: 2.6% (8 of
309) versus 1.5% (32 of 2,113), respectively (p 5 0.17). Hemorrhagic
stroke was a rare event, occurring in 3 patients with and 13 patients
without diabetes. There is no information available regarding hemor-
rhage in the three patients with stroke. Strokes were hemorrhagic in
43% of patients with diabetes and in a similar proportion of those
without diabetes (p 5 0.9). The mortality rate 30 days after myocardial
infarction was 50% (4 of 8) in patients with diabetes who had a stroke
versus 31% (10 of 32) in those without diabetes (p 5 0.3). However,
the cause of death, was considered to be stroke in only one patient, and
this patient did not have diabetes. Contrary to the assertion of Iris and
Villasis, the initial GUSTO-1 angiographic trial report (2) did not state
that 24% of patients died of stroke. Only the number of strokes and
intracranial hemorrhages were reported (2), not mortality as a result of
these events. It is clear from the above data that mortality due to stroke
did not contribute to the excess mortality noted in patients with
diabetes in this trial. We would also like to point out that diabetes was
not an independent determinant of hemorrhagic stroke in the 41,021-
patient GUSTO-1 trial (3).
Iris and Villasis have suggested that the failure to find a difference
in systolic left ventricular function between patients with and without
diabetes despite the higher incidence of heart failure in the diabetic
patient group may have been the result of the subgroup of patients we
chose for ventricular function analysis (i.e., only those with patent
infarct-related arteries 90 min and 5 to 7 days after thrombolysis),
which contained only a small number who developed heart failure. 1)
We would like to point out that as stated in the introduction of the
report, the specific purpose of our study was to determine whether
diabetes has an effect on the response to ischemic injury and subse-
quent reperfusion after myocardial infarction—hence the choice of
that particular subgroup of patients. However, it is correct that there is
no difference in the proportion of patients with and without diabetes
who experienced heart failure during the hospital period in this
particular subgroup (4% vs. 7.4% respectively, p 5 0.4). However,
analysis, of the entire group of patients who underwent ventriculogra-
phy within 24 h of entry into the trial, regardless of infarct-related
artery patency status (215 with, 1,467 without diabetes) demonstrated
no difference in ejection fraction between those with and without
diabetes (58 6 0.4% vs. 57 6 1.0%, respectively, p 5 0.2) despite a
difference in the proportion of those with and without heart failure
(18.7% in those with diabetes vs. 12.1% in those without diabetes, p 5
0.007). Also, similar ejection fractions were noted in this group at 5- to
7-day postinfarction ventriculography in those with and without dia-
betes (58 6 0.4 vs. 57 6 1.3, respectively, p 5 0.4). These data support
our original observation that the difference in heart failure after
myocardial infarction in patients with compared with those without
diabetes is not explained by differences in systolic left ventricular
function. We would also point out that diabetes was not a significant
determinant of either regional or global systolic ventricular function
90 min or 5 to 7 days after thrombolytic therapy by multivariable
analysis (1).
We would agree with the last point raised by Iris and Villasis that
the results of this study may not necessarily apply to all patients with
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